Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 208-436-5 | CAS number: 528-50-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- October 25, 2016, to October 13, 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 017
- Report date:
- 2017
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- version of September 21, 1998
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- D-cellobiose
- EC Number:
- 208-436-5
- EC Name:
- D-cellobiose
- Cas Number:
- 528-50-7
- Molecular formula:
- C12H22O11
- IUPAC Name:
- (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)- 4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol
Constituent 1
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source (i.e. manufacturer or supplier) and lot/batch number of test material: Pfeifer & Langen GmbH & Co. KG, Batch no. CB 20.05.2016
- Purity, including information on contaminants, isomers, etc.: purity > 99%
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: room temperature
Test animals
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories Germany GmbH, Sandhofer Weg 7, 97633 Sulzfeld, Germany
- Age at study initiation: males: 51 days; females: 61 days
- Weight at study initiation: Males: 241.0 g - 285.5 g; Females: 206.8 g - 246.4 g
- Fasting period before study: no reported
- Housing: The animals were kept singly in MAKROLON cages (type III plus) with a basal surface of approx. 39 cm x 23 cm and a height of approx. 18 cm.
- Diet (e.g. ad libitum): ssniff-R/M-H V1534 (ssniff Spezialdiäten GmbH, 59494 Soest, Germany) ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: no reported
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22°C ± 3°C
- Humidity (%): 55% ± 15%
- Air changes (per hr): not reported
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: drinking water
- Details on route of administration:
- The oral route is the default route. In addition, the study was conducted for an application for authorisation of a novel food in accordance with Article 10 of Regulation (EU) 2015/2283.
- Vehicle:
- water
- Analytical verification of doses or concentrations:
- yes
- Remarks:
- Samples of 10 mL of the test item-drinking water mixtures were taken (sterile) in test weeks 1 and 13 and stored at ≤-20°C until shipment for analysis. Germany
- Details on analytical verification of doses or concentrations:
- Samples were shipped to Analytisches Zentrum Biopharm GmbH Dr. Berthold Lausecker, Bitterfelder Str. 19, 12681 Berlin, Germany, and analysed for concentration, stability and homogeneity (GLP-compliant).
- Duration of treatment / exposure:
- 90 days
- Frequency of treatment:
- Continuously (ad libitum) for 90 days
Doses / concentrationsopen allclose all
- Dose / conc.:
- 25 mg/L drinking water
- Remarks:
- 2.5%
- Dose / conc.:
- 50 mg/L drinking water
- Remarks:
- 5%
- Dose / conc.:
- 100 mg/L drinking water
- Remarks:
- 10%
- No. of animals per sex per dose:
- 10 animals/sex/dose
- Control animals:
- yes, concurrent no treatment
- Details on study design:
- - Dose selection rationale: based on a 28-days dose-range finding study
- Post-exposure recovery period in satellite groups: 28-days with 20 rats
- Dose range finding studies: Yes - Positive control:
- none
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: at least once daily
- Cage side observations: Any signs of illness or reaction to treatment were recorded for each individual animal. Cage-side observations included skin/fur, eyes, mucous membranes, respiratory and circulatory systems, somatomotor activity, and behaviour patterns. The onset, intensity and duration of any signs observed were recorded.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: before first exposure and then once per week
- Observations: changes in skin, fur, eyes, mucous membranes, occurrence of secretions and excretions and autonomic activity (e.g. lacrimation, pilo-erection, pupil size, unusual respiratory pattern). Changes in gait, posture and response to handling as well as the presence of clonic or tonic movements, stereotypies (e.g. excessive grooming, repetitive circling) or bizarre behaviour (e.g. self-mutilation, walking backwards) were also recorded.
BODY WEIGHT: Yes
- Time schedule for examinations: The weight of each rat was recorded at the time of group allocation, daily from the day of commencement of treatment up to and including test week 6 for dose adjustment, and thereafter weekly throughout the experimental period.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): Yes
- Time schedule for examinations: daily
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: Examinations were performed on all animals before first dosing, at the end of the main study (test week 13) and at the end of the recovery period (test week 17)
- Dose groups that were examined:all
HAEMATOLOGY: Yes
- Time schedule for collection of blood: at the end of the treatment period and at the end of the recovery period
- Anaesthetic used for blood collection: light ether anaesthesia
- Animals fasted: Yes (overnight)
- How many animals: all
- Parameters checked in table 1 were examined.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: at the end of the treatment period and at the end of the recovery period
- Animals fasted: Yes (overnight)
- How many animals:all
- Parameters checked in table 2 were examined.
PLASMA/SERUM HORMONES/LIPIDS: No
URINALYSIS: Yes
- Time schedule for collection of urine: at the end of the treatment period and at the end of the recovery period
- Metabolism cages used for collection of urine: Not specified
- Animals fasted: Yes
- Parameters examined: volime, pH, specific gravity, Protein, Glucose, Bilirubin, Urobilinogen, Ketones, Haemoglobin (HGB) (approx. values), Nitrite, microscopic examinations (Epithelial cells, Leucocytes, Erythrocytes, Organisms, further constituents (i.e. sperm, casts), Crystalluria)
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: test weeks 13 and 17 (before any blood sampling for laboratory examinations)
- Dose groups that were examined:all
- Battery of functions tested: sensory activity / grip strength / motor activity (for details see Table 3 below)
IMMUNOLOGY: No - Sacrifice and pathology:
- GROSS PATHOLOGY:
On test day 92 (to complete the 24-hour exposure on test days 90/91) the main study animals were dissected following a randomisation scheme. Dissection of all animals allocated to the recovery period was performed on test day 120.
The animals were euthanized by carbon dioxide (CO2) inhalation, exsanguinated by cutting the aorta abdominalis, weighed, dissected and inspected macroscopically under the direction of a pathologist.
All superficial tissues were examined visually and by palpation and the cranial roof was removed to allow observation of the brain, pituitary gland and cranial nerves. After ventral midline incision and skin reflection, all subcutaneous tissues were examined. The condition of the thoracic viscera was noted with due attention to the thymus, lymph nodes and heart.
The abdominal viscera were examined before and after removal, the urinary bladder was examined externally and by palpation. The gastro-intestinal tract was examined as a whole and the stomach and caecum were incised and examined. The lungs were removed and all pleural surfaces examined under suitable illumination. The liver and the kidneys were examined. Any abnormalities in the appearance and size of the gonads, adrenal glands, uterus, intra-abdominal lymph nodes and accessory reproductive organs were recorded.
The weights of the following organs of all animals were determined before fixation:
Adrenal gland (2)
Brain
Epididymis (2)
Heart
Kidney (2)
Liver Ovary (2)
Pancreas
Spleen
Testicle (2)
Thymus
prostate
seminal vesicles with coagulating glands
Uterus (incl. cervix)
Paired organs were weighed individually and identified as left or right. The relative organ weight [g/kg b.w.] was calculated.
HISTOPATHOLOGY: Yes (see table 4) - Optional endpoint(s):
- Optional endpoints: No
- Statistics:
- Data for toxicology and pathology were captured, as far as possible; using the departmental computerized systems (Provantis® Integrated preclinical software, version 9.4.0, Instem LSS Ltd., Stone, Staffordshire ST15 0SD, United Kingdom). Raw data not fully compatible with the computerized systems were maintained on paper according to appropriate SOPs.
The test item groups 2 to 4 were compared to the control group 1. The following statistical methods were used:
- Multiple t-test based on DUNNETT, C. W.
- Exact test of R. A. FISHER (if applicable)
The following settings were used for the statistical evaluation of the parametricvalues captured by Provantis:
Homogeneity of variances and normality of distribution were tested using the BARTLETT’s and SHAPIRO-WILKS test. In case of heterogeneity and/or non- normality of distribution, stepwise transformation of the values into logarithmic or rank values was performed prior to ANOVA. If the ANOVA yielded a significant effect (p ≤ 0.05), intergroup comparisons with the control group was made by the DUNNETT’s test (p ≤ 0.01 and p ≤ 0.05).
The following statistical methods were used for the data not captured with the Provantis system, i.e. Numerical functional tests: Body temperature / Hind leg splay / Grip strength / Spontaneous motility): STUDENT's t-test
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Treatment period (Table 1a):
The body weight, body weight gain and body weight at autopsy were not influenced in male animals treated with a concentration of 2.5% Cellobiose in drinking water and in female animals treated with concentrations of 2.5%, 5% or 10% Cellobiose in drinking water for 90 days compared to the control group.
The body weight of the male animals treated with a concentration of 5% Cellobiose in drinking water for 90 days was marginally reduced by up to 6% compared to the control group (statistically not significant at p ≤ 0.05) as of test day 15. The body weight gain from start (test day 1) to the end of test day 91 was 103% compared to 113% of the animals of the control group. Body weight at autopsy appeared not to be influenced. Female animals were not affected.
The body weight of the male animals treated with a concentration of 10% Cellobiose in drinking water for 90 days was slightly reduced by 5% to 7% compared to the control group (statistically significant at p ≤ 0.01 on test day 8 and at p ≤ 0.05 on test days 15, 22, 50, 57 and 64) as of test day 8. Body weight gain from start (test day 1) to the end of test day 91 was 100% compared to 113% of the animals of the control group. Body weight at autopsy was marginally reduced by 5% compared to the control group. Female animals were not affected.
Recovery period (Table 1b):
The body weight of male animals previously treated with a concentration of 10% Cellobiose in drinking water for 90 days was still marginally reduced by 5% com- pared to the control group (statistically not significant at p ≤ 0.05) during the 28-day treatment-free recovery period, however, body weight gain revealed a tendency towards normalisation. - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Treatment period:
No test item-related influence was noted on relative food consumption of male animals treated with a concentration of 2.5% Cellobiose in drinking water for 90 days compared to the control group.
The relative food consumption of female rats treated with a concentration of 2.5% Cellobiose in drinking water and of male and female rats treated with concentrations of 5% or 10% Cellobiose in drinking water for 90 days was decreased in a dose-related way.
A marginal reduction (5% to 7% below the female control animals) was noted for the relative food consumption of low-dose-females (2.5% Cellobiose in drinking water) in test weeks 1 to 11 (statistically significant at p ≤ 0.05 or p ≤ 0.01 in test weeks 1 to 8).
A slightly decreased food intake (at maximum 10% or 13% below the control group) was noted for male and female animals treated with a concentration of 5% Cellobiose in drinking water during the 90-day treatment period (statistically significant at p ≤ 0.05 or p ≤ 0.01 except test weeks 9 and 13 (males) and test week 12 (females)).
Moderately decreased food consumption (at maximum 17% or 22% below the control group) was noted for male and female rats treated with a concentration of 10% Cellobiose in drinking water for 90 days (statistically significant at p ≤ 0.01).
Recovery period:
The relative food consumption of male and female rats previously treated with a concentration of 10% Cellobiose in drinking water for 90 days increased again to or slightly above the values consumed by the control group during the 28-day treatment-free recovery period.
Statistically significant differences in relative food consumption compared to the control (slight increase in test weeks 14 and 17) were not considered to be test item-related, as they were slight alterations in comparison to control animals is without any biological relevance and observed in females only.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- effects observed, treatment-related
- Description (incidence and severity):
- Treatment period:
No test-item-related influence was noted on the relative and absolute drinking water consumption of the male and female animals treated with a concentration of 2.5% Cellobiose in drinking water and of the female animals treated with a concentration of 5% Cellobiose in drinking water for 90 days compared to the control group.
A marginal reduction (up to 19% below male control animals) was noted for the absolute drinking water consumption of mid-dose male rats (5% Cellobiose in drinking water) on few test days as of test week 2 (statistically significant at p ≤ 0.05 or p ≤ 0.01 on test days 8→9, 9→10, 14→15, 15→16, 18→19, 23→24, 31→32, 35→36, 38→39, 43→44 and 77→78). The weekly relative drinking water consumption of mid-dose males was not influenced.
Moderately decreased relative drinking water consumption (at maximum 16% or 26% below the control group) was noted for male and female rats treated with a concentration of 10% Cellobiose in drinking water for 90 days (statistically significant at p ≤ 0.01 or p ≤ 0.05 in test weeks 1 to 6 and 12 for males and in test weeks 1 to 8 and 10 for females). The daily absolute drinking water consumption was decreased at a maximum of 34% and 33% for male and female animals, respectively, compared to the control group (statistically significant at p ≤ 0.05 or p ≤ 0.01 on several test days).
Recovery period:
The drinking water consumption of male and female rats previously treated with a concentration of 10% Cellobiose in drinking water for 90 days increased again to or slightly above the values consumed by the control group during the 28-day treatment-free recovery period. Statistically significant increases in drinking water consumption compared to the control which were considered to be not test item-related, as they were slight alterations in comparison to control animals without any biological relevance and observed in females only. - Ophthalmological findings:
- no effects observed
- Description (incidence and severity):
- No changes of the eyes and the optic region, i.e. adnexa oculi, conjunctiva, cornea, anterior chamber, lens, vitreous body and fundus were noted in the male and female rats of the main study treated with concentrations of 2.5%, 5% or 10% Cellobiose in drinking water for 90 days or of the recovery animals previously treated with a concentration of 10% Cellobiose in drinking water.
There was no indication of any impairment to auditory acuity. - Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No test-item-related influence was observed for the haemoglobin content (HGB), the number of erythrocytes (RBC), leucocytes (WBC) and platelets (PLT), the percentage of reticulocytes (Reti), the haematocrit value (HCT), the relative and absolute count of neutrophilic granulocytes (Neut), lymphocytes (Lym), monocytes (Mono), eosinophilic granulocytes (Eos), large unstained cells (LUC) and basophilic granulocytes (Baso), the thromboplastin time (TPT), the activated partial thromboplastin time (aPTT), the mean corpuscular volume (MCV), the mean corpuscular haemoglobin (MCH), and the mean corpuscular haemoglobin concentration (MCHC).
Some statistically significant differences in haematological parameters compared to the control were considered to be not test item-related (see Table 2) - Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No test item-related influence was noted for the plasma levels of albumin and globulin, the albumin/globulin ratio, the plasma levels of bile acids, bilirubin, cholesterol, creatinine, glucose, protein (total), triglycerides, urea, calcium, chloride, potassium and sodium. Further, the plasma activity of alanine aminotransferase (ALAT), alkaline phosphatase (aP), aspartate aminotransferase (ASAT), lactate dehydrogenase (LDH) and gamma-glutamyl-transferase (Gamma-GT) was not influenced.
Statistically significant decreases in clinical chemistry parameters compared to the control were considered to be not test item-related (Table 3). - Endocrine findings:
- not examined
- Urinalysis findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No test-item-related changes were noted for specific gravity and pH value of urine, and urine volume. The analyte concentrations of nitrite, protein, glucose, ketones, urobilinogen, bilirubin and haemoglobin were not influenced in male and female animals. No test-item-related changes were observed in urine colour and microscopically analysed urine sediments.
The statistical significance of the differences in urinary parameters compared to the control (increase in specific gravity in low dose group and decrease in urine volume in low dose group) were considered to be not test item-related, as they lacked a dose-response. - Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- Treatment period / Recovery period
The neurological screening performed at the end of the treatment period in test week 13 did not reveal any test item-related influence in male and female rats treated with concentrations of 2.5%, 5% or 10% Cellobiose in drinking water, neither on any of the parameters examined during the functional observation tests nor on the fore- and hind limb grip strength or on the spontaneous motility. Furthermore, no test item-related influence was noted in rats previously treated with a concentration of 10% Cellobiose in drinking water at the end of the recovery period in test week 17. - Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- No test-item-related influence was noted on the relative and absolute organ weights of male and female animals treated with concentrations of 2.5%, 5% or 10% Cellobiose in drinking water for 90 days compared to the control group, neither at the end of the treatment period on test day 92 nor at the end of the 28-day treatment-free recovery period on test day 120.
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- Treatment period:
No test-item-related influence was noted for male and female rats treated with concentrations of 2.5%, 5% or 10% Cellobiose in drinking water for 90 days at terminal sacrifice on test day 92.
Macroscopic changes were noted in the ovary (cystic), pancreas (pale / reddened), pituitary (enlarged), spleen (enlarged), stomach mucosa (reddened), thymus (reddened) and uterus (dilated) in individual animals of test-item-treated groups and the control group. These changes are considered to be incidental findings due to the low number of animals affected. Similar findings were also noted in control groups of subchronical / chronical rat studies at the same laboratory.
Recovery period:
No test-item-related pathological changes were observed in the organs of male and female rats previously treated with a concentration of 10% Cellobiose in drinking water for 90 days at the end of the 28-day recovery period.
Macroscopic changes were noted in the pituitary (enlarged) or uterus (dilated, filled with clear liquid) in 2 of 5 female animals of the previously high-dose group. These changes are considered to be incidental findings due to the low number of animals affected. - Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- Treatment period / Recovery period (restricted to group 1 (control) and group 4 (high dose)):
The histopathological examination was restricted to a variety of organs and tissues from the control and the high dose animals (groups 1 and 4).
Histological examination did not reveal any morphological changes in animals treated with a concentration of 10% Cellobiose in drinking water for 90 days which are considered to be related to the administration of the test item. No test- item-related changes were noted at the end of the 28-day recovery period.
A few minor microscopic changes were recorded for the organs and tissues exam- ined in this study. However, the type, incidence and severity of all microscopic findings observed did not indicate any relationship to treatment with the test item. All changes noted are regarded as spontaneous and to be within the normal back- ground pathology commonly seen in rats of this strain and age. - Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- not examined
Effect levels
open allclose all
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 8 043 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- female
- Remarks on result:
- other: All observed effects, i.e., marginally reduced body weight and food consumption, are considered to be secondary to a reduced drinking water intake at the highest dose level.
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 6 852 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male
- Remarks on result:
- other: All observed effects, i.e., marginally reduced body weight and food consumption, are considered to be secondary to a reduced drinking water intake at the highest dose level.
Target system / organ toxicity
- Key result
- Critical effects observed:
- no
Any other information on results incl. tables
Table 1a: Bodyweight males (treatment period) (Anova & Dunnett: * = p ≤ 0.05; ** = p ≤ 0.01)
Day(s) Relative to Start Date | ||||||||||||||||
-6 | 1 | 8 | 15 | 22 | 29 | 36 | 43 | 50 | 57 | 64 | 71 | 78 | 85 | 91 | ||
Group 1: | Mean | 195.47 | 262.37 | 320.77 | 362.18 | 396.45 | 427.23 | 450.26 | 473.98 | 492.95 | 508.96 | 525.04 | 535.34 | 540.44 | 549.90 | 558.73 |
Control | SD | 8.43 | 10.93 | 13.14 | 18.52 | 19.04 | 25.23 | 28.40 | 30.13 | 32.44 | 34.65 | 38.09 | 39.18 | 42.41 | 40.01 | 42.81 |
N | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | |
Group 2: | Mean | 195.94 | 262.54 | 322.50 | 367.02 | 403.12 | 436,74 | 459.24 | 481.73 | 497.07 | 509.50 | 525.36 | 535.09 | 536.95 | 545.00 | 555.59 |
2.5% | SD | 7.54 | 10.86 | 11.93 | 14.68 | 19.74 | 26.35 | 26.92 | 30.80 | 27.88 | 35.15 | 41.00 | 41.96 | 44.37 | 50.20 | 53.53 |
N | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | |
%Diff | 0.2 | 0.1 | 0.5 | 44621 | 44743 | 44594 | 2.0 | 1.6 | 0.8 | 0.1 | 0.1 | 0.0 | -0.6 | -0.9 | -0.6 | |
Group 3: | Mean | 196.62 | 261.64 | 310.16 | 347.85 | 377.81 | 405.19 | 426.22 | 448.05 | 464.98 | 483.42 | 499.90 | 509.79 | 512.91 | 519.13 | 530.91 |
5% | SD | 5.15 | 9.96 | 15.56 | 16.74 | 18.18 | 21.07 | 24.08 | 28.58 | 32.88 | 35.42 | 31.82 | 33.23 | 35.12 | 37.12 | 38.96 |
N | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | |
%Diff | 0.6 | -0.3 | -3.3 | 4.0 | -4.7 | -5.2 | -5.3 | -5.5 | -5.7 | -5.0 | -4.8 | -4.8 | -5.1 | -5.6 | -5.0 | |
Group 4: | Mean | 197.13 | 263.30 | 303.37 ** | 343.16* | 374.75* | 404.65 | 425.33 | 447.37 | 460.37* | 472.35* | 486.29* | 502.35 | 505.16 | 516.72 | 526.89 |
10% | SD | 7.21 | 7.97 | 13.45 | 21.70 | 27.61 | 30.32 | 31.66 | 31.54 | 33.00 | 36.39 | 40.13 | 39.94 | 38.59 | 38.60 | 39.43 |
N | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | |
%Diff | 0.8 | 0.4 | -5.4 | -5.3 | -5.5 | -5.3 | -5.5 | -5.6 | -6.6 | -7.2 | -7.4 | -6.2 | -6.5 | -6.0 | -5.7 |
Sex: Male | Day(s) Relative to Start Date | |||||
98 | 105 | 112 | 119 | |||
Group 1 : | Mean | 568.92 | 585.30 | 593.18 | 595.30 | |
Control | SD | 47.56 | 54.03 | 54.75 | 53.21 | |
N | 5 | 5 | 5 | 5 | ||
Group 4' | Mean | 540.30 | 555.48 | 565.94 | 568.42 | |
10% | SD | 35.68 | 33.81 | 33.18 | 35.47 | |
N | 5 | 5 | 5 | 5 | ||
%Diff | -5.0 | -5.1 | -4.6 | -4,5 |
Table 2: Statistically significant differences in haematological parameters not test-item related (A: the slight alteration in comparison to control animals is without any biological relevance; B: lacking dose dependence; C: only one gender affected)
Parameter | Increase (I) | Group/ | Test day | Statistical significance | Reason |
Decrease (D) | Sex | ||||
Haemoglobin content (HGB) | D | 3 f | 92 | p < 0.05 | A, C |
D | 4 f | 92 | p < 0.01 | A, C | |
Erythrocytes /RBC) | D | 3 f | 92 | p < 0.05 | A |
D | 4 m | 92 | p < 0.01 | A | |
D | 4 f | 92 | p < 0.01 | A | |
Platelets (PLT) | I | 2 f | 92 | p < 0.01 | B, C |
I | 4 f | 92 | p < 0.05 | A, C | |
Haematocrit value (HCT) | D | 3 f | 92 | p < 0.05 | A, C |
D | 4 f | 92 | p < 0.01 | A, C | |
Activated partial thromboplastin time (aPTT) | I | 4 f | 92 | p < 0.01 | A, C |
Table 3: Statistically significant decreases in clinical chemistry parameters not test-item related (A: the slight alteration in comparison to control animals is without any biological relevance; B: lacking dose dependence; C: enzyme reduction without any toxological relevance ;D: only one gender affected)
Parameter | Group/ | Test day | Statistical | Reason |
Sex | significance | |||
Bilirubin | 4 m | 120 | p < 0.01 | A, C, D |
Chloride | 4 f | 120 | p < 0.05 | B, D |
Sodium | 4 f | 120 | p < 0.05 | A, D |
Gamma-GT | 4 m | 120 | p < 0.05 | A, C, D |
Applicant's summary and conclusion
- Conclusions:
- In a GLP-compliant study according to OECD TG 408 in rats, cellobiose administered via drinking water did not induce any adverse effects. The experimental no-observed-adverse-effect level (NOAEL) was equal to or greater than 10% Cellobiose in drinking water (equivalent to ~ 6852 and ~ 8043 mg Cellobiose per kg body weight for males and females, respectively).
- Executive summary:
In a GLP-compliant study according to OECD TG 408 in rats, cellobiose administered via drinking water did not induce any adverse effects. The experimental no-observed-adverse-effect level (NOAEL) was equal to or greater than 10% Cellobiose in drinking water (equivalent to ~ 6852 and ~ 8043 mg Cellobiose per kg body weight for males and females, respectively). All observed effects, i.e., marginally reduced body weight and food consumption, are considered to be secondary to a reduced drinking water intake at the highest dose level.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.